Skye Bioscience Inc (SKYE)

[Closewatcher]

I thought the analysis on this board regarding Inmed & Nemus has been pretty accurate. I have to agree with Vinpat in regards to the fact that their biosynthesis is wildly inflated and may not be that beneficial as opposed to what other companies are doing.

Their entire claim behind their technology/software is speed, which is that their process allows them to identify cannabinoids best suited for certain diseases without doing heavy amount of trials and research. Theoretically, this would mean that they would be able to identify a variety of targets faster than any other company, or so they claim.

However, right now they have only two targets in their pipeline, meanwhile they've been at it with this system of biosynthesis for years.

See below for Seeking Alpha article from March 2015. They have essentially missed all expected timelines and are not much further along then they were over 2 years ago. Their pipeline has actually shrinked, and they haven't advanced on those targets.

https://seekingalpha.com/instablog/27523743-point-of-return/3789506-all-natural-the-opportunity-in-pharmaceutical-cannabinoid-medicine-with-inmed-pharmaceuticals-inc

If their science was that superb, you'd think they would have been further along or wouldve been able to secure more funding by now. The 5 million raise will keep them afloat for now but they are clearly very far behind in moving towards trials.